Collectively, these findings tied together experimental findings in mice and human clinical data and lent support to the notion that the p53-USP19-SOAT1 axis is dysregulated in HCC, contributes to disease progression, impacts long-term survival, and could be a relevant therapeutic target (Figure 1). The gene discussed is TP53; the disease is hepatocellular carcinoma.